ASSTON PHARMACEUTICALS IPO is a fully book-built issue and the total IPO size is ₹27.56 crores. The total offering consists of 2,241,600 shares.
The ASSTON PHARMACEUTICALS IPO will open on July 9, 2025 and close on July 11, 2025.
The allotment process is expected to be finalized by July 14, 2025. The ASSTON PHARMACEUTICALS IPO is scheduled to list on BSE SME, with a tentative listing date of July 16, 2025.
The price band for the ASSTON PHARMACEUTICALS IPO is ₹115–₹123 per share.
Registrar for this IPO is MAASHITLA SECURITIES PRIVATE LIMITED and lead manager for ASSTON PHARMACEUTICALS IPO is SOBHAGYA CAPITAL OPTIONS PRIVATE LIMITED.
Explore more upcoming IPOs in India for comparison and investment planning.
IPO Schedule
| IPO Open Date | Wednesday, 09 Jul, 2025 |
|---|---|
| IPO Close Date | Friday, 11 Jul, 2025 |
| IPO Allotment Date | Monday, 14 Jul, 2025 |
| Refund Initiation | Tuesday, 15 Jul, 2025 |
| Share credit in Demat | Tuesday, 15 Jul, 2025 |
| Listing Date | Wednesday, 16 Jul, 2025 |
Key Details
| Price Band | ₹115 to ₹123 Per Share |
|---|---|
| Lot Size | 1000 Shares |
| Face Value | ₹10 Per Equity Share |
| Total Issue Size | 2,241,600 Shares |
| Fresh Issue | 2,241,600 Shares |
| Issue Type | Fresh Issue |
| Listing At | BSE SME |
Share Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB | 50% |
| Retail | 35% |
| NII/HNI | 15% |
Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 1000 | 123,000 |
| Retail (Max) | 1 | 1000 | 123,000 |
| S-HNI (Min) | 2 | 2000 | 246,000 |
| S-HNI (Max) | 8 | 8000 | 984,000 |
About ASSTON PHARMACEUTICALS LIMITED Company
Asston Pharmaceuticals Limited is engaged in the manufacturing and export of pharmaceutical formulations and nutraceutical products, primarily targeting domestic and African markets. Operating under the "Asston" brand, the company produces tablets, capsules, oral liquids, external preparations, and oral powders. They also offer contract manufacturing services. Production takes place at their Ambernath, Maharashtra facility, with dedicated floors for pharmaceutical and nutraceutical products, adhering to stringent FDA and FSSAI standards. The facility has a capacity of around 8-9 crore tablets per month.
Asston also utilizes WHO-GMP certified contract manufacturers for generic medicines and antibiotics and maintains tie-ups with NABL accredited labs. With over 150 registered trademarks, their products include capsules, syrups, sachets, and injectables, sold globally to pharmacies. Revenue generation is through export sales, contract manufacturing/loan license arrangements, and domestic sales. They focus on delivering affordable, quality products. As of November 30, 2024, Asston Pharmaceuticals had an order book worth USD 223,000 (approximately 1.86 crore INR).
ASSTON PHARMACEUTICALS LIMITED Financial Details
| Period Ended | 30 Nov 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 247.36 | 202.60 | 136.94 | 94.91 |
| Revenue | 20.68 | 15.59 | 6.54 | 9.60 |
| Profit After Tax | 33.75 | 13.60 | 10.57 | 1.11 |
| Net Worth | 97.67 | 63.93 | 19.86 | 9.29 |
| Reserves and Surplus | 34.96 | 56.09 | 12.86 | 2.29 |
| Total Borrowing | 69.71 | 68.20 | 52.45 | 33.10 |
₹ In Crore
Key Performance Indicator
| Basic EPS (in ₹) | Return on Net Worth (RoNW) | Net Asset Value (NAV) | Debt-Equity Ratio | Return on Equity (ROE) | Return on Capital Employed (ROCE) |
|---|---|---|---|---|---|
| 2.37 | 21.28% | 10.19 | 1.07 | 32.47% | 34.29% |
Offer Objectives
The IPO aims to raise funds for several key objectives. A significant portion, ₹600 lakhs, equivalent to ₹6 crore, is earmarked for acquiring machinery to enhance the manufacturing unit in Rajkot, Gujarat.
Working Capital and Debt Reduction: Another substantial allocation of ₹1,300 lakhs (₹13 crore) will be used to meet the incremental working capital needs. Furthermore, ₹100 lakhs (₹1 crore) is dedicated to the repayment and/or prepayment of outstanding borrowings. The expenditures are planned for Fiscal Years 2025 and 2026, with working capital needs primarily addressed in Fiscal 2026.
General Corporate Purposes: A portion of the proceeds will be allocated for general corporate purposes. The amount for these purposes will not exceed 15% of the gross proceeds from the Issue, complying with SEBI ICDR Regulations.
Machinery Details: The company intends to purchase and install new machineries from Khandelwal Pharma and Cosmetic Equipments with a total value of ₹4,80,56,000 (₹48.056 crore), including items like rapid mixer granulators, fluid bed dryers, octagonal blenders, vibro sifters, multi mills, paste kettles, coating pans, double rotary tabletting machines, blistering packing machines and striping machines.
Flexibility and Monitoring: The management retains flexibility in utilizing the Net Proceeds, and deployment is based on management estimates without independent appraisal. Unutilized funds will be deployed in subsequent fiscals, ensuring adherence to SEBI regulations regarding the use of issue proceeds.
Company Details
Address:
4th Floor, Office No . A-431 Balaji Bhavan, Plot No 42A Sector -11 CBD Belapur, Navi Mumbai, Thane 400 614, Maharashtra, India.
Phone: +91 22 49731411,+91 224973 1419
Email: [email protected]
Website: http://www.asstonpharmaceuticals.com
IPO Registrar Details
MAASHITLA SECURITIES PRIVATE LIMITED
Phone: +91 11 45121795/96 ,+91 22 488 08634,+91 11 47581432
Email: [email protected]
Website: http://www.maashitla.com
Offer Prospectus & Documents
Lead Managers
- SOBHAGYA CAPITAL OPTIONS PRIVATE LIMITED
